AN2 director buys 2,098 ANTX shares at $5.53

AN2 Therapeutics, Inc. (ANTX) director Margaret M. FitzPatrick purchased 2,098 shares of ANTX common stock in a direct open-market or private transaction on September 1, 2026 at $5.53 per share.

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. (ANTX) director Margaret M. FitzPatrick purchased 2,098 shares of ANTX common stock in a direct open-market or private transaction on September 1, 2026 at $5.53 per share. Following this purchase, she directly holds 10,708 shares of ANTX common stock. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 2,098 shares

Net Buy 1 txn

Insider FitzPatrick Margaret M

Role Director

Bought 2,098 shs ($12K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,098	$5.53	$12K

Holdings After Transaction: Common Stock — 10,708 shares (Direct)

Key Figures

Shares purchased: 2,098 shares Purchase price per share: $5.53 per share Shares owned after transaction: 10,708 shares

3 metrics

Shares purchased 2,098 shares Common stock bought by director on September 1, 2026

Purchase price per share $5.53 per share Open-market or private purchase of ANTX common stock

Shares owned after transaction 10,708 shares Director’s direct holdings following the September 1, 2026 trade

Key Terms

Common Stock, open market or private transaction, Rule 10b5-1

3 terms

Common Stock financial

"Common Stock purchased and held directly by the director"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"Purchase in open market or private transaction"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did ANTX director Margaret M. FitzPatrick report?

She reported a purchase of 2,098 shares of AN2 Therapeutics common stock on September 1, 2026 in an open-market or private transaction at $5.53 per share.

How many ANTX shares does the director own after this Form 4 transaction?

After the reported transaction, Margaret M. FitzPatrick directly owns 10,708 shares of AN2 Therapeutics common stock, according to the filing’s post-transaction holdings figure.

Was the ANTX insider trade made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 trading plan is associated with this transaction, as the document-level checkbox for such a plan is not marked as affirmed.

What was the price paid per share in the ANTX insider purchase?

The director paid $5.53 per share for the 2,098 shares of AN2 Therapeutics common stock acquired on September 1, 2026, with the price reported as a per-share amount.

Is this ANTX Form 4 transaction a buy or a sell?

This Form 4 reports a buy transaction. It is coded as a purchase in an open-market or private transaction, with 2,098 shares acquired and no shares reported as sold in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 06:44 PM Accepted by SEC EDGAR 09/02/2026 - 06:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FitzPatrick Margaret M

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		P		2,098	A	$5.53	10,708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lucy Day, Attorney-in-Fact for Margaret M. FitzPatrick	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)